View New Articles By
Adam de la Zerda, PhD (Dale F. Frey Scientist ‘13, Damon Runyon Fellow ‘11-‘12) of Stanford University, Stanford, was named to the Forbes Magazine “30 Under 30” list in Science and Healthcare for 2014. Adam is using sound waves to image the body at the molecular level, applying the technology to take pictures of brain tumors, blood, and living mice. Those on this list are described as the “brightest young stars” of their generation.
A team of researchers including Akinyemi I. Ojesina, MBBS, PhD (Damon Runyon Fellow ‘08-‘11) and Matthew L. Meyerson, MD, PhD (Damon Runyon Fellow ‘95-‘98) of Dana-Farber Cancer Institute and the Broad Institute, Cambridge, reported genome sequencing results for 115 cervical cancer patient tumor samples. The researchers identified genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments exist for other forms of cancer.
Nathanael S. Gray, PhD (Damon Runyon-Rachleff Innovator ‘08-‘10), of Dana-Farber Cancer Institute, Boston, was honored as the recipient of the prestigious 2013 Meyenburg Cancer Research Award. He was recognized for his groundbreaking work in developing first-in-class chemical inhibitors for protein kinases, which are potential targets to treat cancer and other diseases.
Election to the Institute of Medicine is one of the highest honors that can be earned in the fields of medicine and health. In recognition of their outstanding achievements, two Damon Runyon alumni were inducted this month:
Helen M. Piwnica-Worms, PhD (Damon Runyon Fellow ‘84-‘85, Former Fellowship Award Committee Member), The University of Texas MD Anderson Cancer Center, Houston
Danny F. Reinberg, PhD (Damon Runyon Fellow ‘83-‘85), New York University School of Medicine, New York City
James E. Rothman, PhD (Damon Runyon Fellow ‘76-‘78) of Yale University, New Haven, was named a recipient of the 2013 Nobel Prize in Physiology or Medicine. He shares the honor with Randy W. Schekman (Former Damon Runyon Fellowship Sponsor) and Thomas C. Südhof “for their discoveries of machinery regulating vesicle traffic, a major transport system in our cells.” Dr. Rothman is the twelfth Damon Runyon Scientist to be named a Nobel Laureate.
The intent of the NIH High-Risk High-Reward Research Awards is to encourage investigators to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health. We congratulate the Damon Runyon scientists who are recipients of these awards.
2013 NIH Pioneer Awards:
Michael Z. Lin, MD, PhD (Damon Runyon-Rachleff Innovator ‘13-‘15), Stanford University, Stanford
Mark J. Zylka, PhD (Damon Runyon Fellow ‘00-‘03), University of North Carolina, Chapel Hill
Andrew T. Chan, MD, MPH (Damon Runyon Clinical Investigator ‘08-‘13) of Massachusetts General Hospital, Boston, and colleagues at the Harvard School of Public Health reported the results of a large, long-term study demonstrating that 40% of all colorectal cancers could be prevented through regular colonoscopy screening. The new research also supports existing guidelines recommending that people with an average risk of colorectal cancer should have a colonoscopy every 10 years. The study was published in the New England Journal of Medicine.
The W. M. Keck Foundation awarded 2013 Medical Research Program Grants to scientists conducting high-risk research with the potential for transformative impact. Three Damon Runyon scientists received grants of $1,000,000 each:
Sreekanth H. Chalasani, PhD (Damon Runyon Fellow ‘04-‘07), Salk Institute, La Jolla
Joshua E. Elias, PhD (Damon Runyon-Rachleff Innovator ‘11-‘13), Stanford University, Stanford
Feng Zhang, PhD (Damon Runyon-Rachleff Innovator ‘12-‘14), Broad Institute, Cambridge
Catherine J. Wu, MD (Damon Runyon Clinical Investigator ‘07-‘12) and colleagues at Dana-Farber Cancer Institute, Boston, reported the success of a new strategy to boost leukemia patients’ immune systems after transplant. In a phase I clinical study, patients with advanced chronic lymphocytic leukemia (CLL) were given a “personalized” tumor vaccine composed of their own inactivated leukemia cells combined with an immune stimulant called GM-CSF.
Andrew T. Chan, MD, MPH (Damon Runyon Clinical Investigator ‘08-‘13) of Massachusetts General Hospital, Boston, and colleagues, reported that the association between aspirin use and risk of colorectal cancer was affected by mutation of the gene BRAF. Researchers found that regular aspirin use was associated with a lower risk of BRAF-wild-type colorectal cancer but not with risk of BRAF-mutated cancer. These results were published in the journal JAMA.
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
